Novartis' atrasentan shows to reduce proteinuria in Phase III IgAN trial
Atrasentan’s safety profile in the trial was deemed favourable, aligning with previous data.
Source: yahoo.com
Metabolism Development Unit News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Metabolism Development Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Metabolism Development Unit Today - Breaking & Trending Today
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Source: prnewswire.com
Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
Source: finanznachrichten.de
Iptacopan Demonstrates 38.3% Proteinuria Reduction in Patients With IgAN
Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.
Source: pharmacytimes.com
Iptacopan Meets Primary End Point of APPOINT-PNH Trial in Paroxysmal Nocturnal Hemoglobinuria
Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.
Source: ajmc.com